Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
UBS
Chinese Patent Office
Covington
Farmers Insurance
US Department of Justice
Chubb
McKinsey
AstraZeneca
Medtronic

Generated: October 24, 2017

DrugPatentWatch Database Preview

PMB 400 Drug Profile

« Back to Dashboard

Which patents cover Pmb 400, and when can generic versions of Pmb 400 launch?

Pmb 400 is a drug marketed by Wyeth Ayerst and is included in one NDA.

The generic ingredient in PMB 400 is estrogens, conjugated; meprobamate. There are three drug master file entries for this compound. Additional details are available on the estrogens, conjugated; meprobamate profile page.

Summary for Tradename: PMB 400

US Patents:0
Applicants:1
NDAs:1
Bulk Api Vendors: see list23
Clinical Trials: see list2,248
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:PMB 400 at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wyeth Ayerst
PMB 400
estrogens, conjugated; meprobamate
TABLET;ORAL010971-003Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: PMB 400

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Wyeth Ayerst
PMB 400
estrogens, conjugated; meprobamate
TABLET;ORAL010971-003Approved Prior to Jan 1, 1982► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Healthtrust
Federal Trade Commission
Baxter
Cerilliant
Argus Health
Harvard Business School
Deloitte
Accenture
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot